Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 11/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694659 | 1.00 | KCNJ1 (0.40) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL7593060 | 0.90 | GPR119 (0.49) | KCNJ1GPR119 | |
| SCHEMBL3687098 | 0.83 | GPR119 (0.42) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL7592847 | 0.83 | GPR119 (0.42) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL7587789 | 0.83 | GPR119 (0.40) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL3690019 | 0.83 | KCNJ1 (0.37) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL3691202 | 0.83 | GPR119 (0.40) | KCNJ1GPR119ALDH1A1KMT2AMEN1 | |
| SCHEMBL7589821 | 0.82 | GPR119 (0.49) | KCNJ1GPR119KCNH2 | |
| SCHEMBL3685203 | 0.82 | GPR119 (0.49) | KCNJ1GPR119KCNH2 | |
| SCHEMBL13955302 | 0.81 | KCNJ1 (0.41) | KCNJ1GPR119ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185544-B1 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2014-11-26 | — | — | EP | claimed |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2012-12-20 | — | — | US | disclosed |
| US-8183381-B2 | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | METABOLEX INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009014910-A2 | N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137590-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | KCNJ1 2412/4885GPR119 1/4885ALDH1A1 2066/4885 |
| US-20120322804-A1 | N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | KCNJ1 2412/4885GPR119 1/4885ALDH1A1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.